Analyst Michael Ulz of Morgan Stanley maintained a Buy rating on Dyne Therapeutics (DYN – Research Report), retaining the price target of $52.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Michael Ulz has given his Buy rating due to a combination of factors including the promising long-term data for Dyne Therapeutics’ DYNE-251. The updated results from the Ph1/2 DELIVER study indicate sustained functional benefits for patients with Duchenne muscular dystrophy (DMD), without any new safety concerns.
Additionally, the completion of enrollment in the registrational expansion cohort and the anticipated timeline for data release and accelerated approval filing further support the positive outlook. The company’s presentation at the upcoming Muscular Dystrophy Association conference is expected to highlight these advancements, reinforcing confidence in the therapeutic potential of DYNE-251. Overall, the combination of clinical progress, safety profile, and strategic milestones underpins the Buy rating for Dyne Therapeutics.
In another report released yesterday, Chardan Capital also reiterated a Buy rating on the stock with a $50.00 price target.
DYN’s price has also changed dramatically for the past six months – from $34.600 to $12.310, which is a -64.42% drop .